These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36970171)

  • 41. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
    SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
    Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
    von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
    J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma.
    Incekara F; Smits M; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Kros JM; Vincent AJPE; van den Bent M
    Front Oncol; 2020; 10():1087. PubMed ID: 32766140
    [No Abstract]   [Full Text] [Related]  

  • 46. MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma.
    Barnett AE; Ozair A; Bamashmos AS; Li H; Bosler DS; Yeaney G; Ali A; Peereboom DM; Lathia JD; Ahluwalia MS
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611052
    [No Abstract]   [Full Text] [Related]  

  • 47. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis.
    Yin AA; Zhang LH; Cheng JX; Dong Y; Liu BL; Han N; Zhang X
    PLoS One; 2014; 9(1):e85102. PubMed ID: 24454798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.
    Egaña L; Auzmendi-Iriarte J; Andermatten J; Villanua J; Ruiz I; Elua-Pinin A; Aldaz P; Querejeta A; Sarasqueta C; Zubia F; Matheu A; Samprón N
    Sci Rep; 2020 Oct; 10(1):18445. PubMed ID: 33116181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
    Feldheim J; Kessler AF; Feldheim JJ; Schulz E; Wend D; Lazaridis L; Kleinschnitz C; Glas M; Ernestus RI; Brandner S; Monoranu CM; Löhr M; Hagemann C
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
    Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
    Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide.
    Chai RC; Chang YZ; Wang QW; Zhang KN; Li JJ; Huang H; Wu F; Liu YQ; Wang YZ
    Front Genet; 2019; 10():910. PubMed ID: 31611911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved risk stratification in younger
    Unger K; Fleischmann DF; Ruf V; Felsberg J; Piehlmaier D; Samaga D; Hess J; Suresh MP; Mittelbronn M; Lauber K; Budach W; Sabel M; Rödel C; Reifenberger G; Herms J; Tonn JC; Zitzelsberger H; Belka C; Niyazi M
    Neurooncol Adv; 2020; 2(1):vdaa137. PubMed ID: 33305269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    Kurdi M; Butt NS; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Dallol A; Mohamed F; Bari MO; Samkari A; Lary AI; Alkhayyat S
    J Neurooncol; 2021 May; 152(3):541-549. PubMed ID: 33661424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
    Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
    Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients.
    Chen X; Yan Y; Zhou J; Huo L; Qian L; Zeng S; Li Z; Wei J; Xu Z; Gong Z
    Ann Transl Med; 2019 Oct; 7(20):541. PubMed ID: 31807523
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.